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ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) and other carcinomas are hierarchically organized 
with cancer stem cells (CSC) residing at the top of the hierarchy where they drive tumor progression, 
metastasis and chemoresistance. Since CSC and non-CSC share an identical genetic background, we 
hypothesize that differences in epigenetics account for the striking functional differences between these 
two cell populations. Epigenetic mechanisms such as DNA methylation play an important role in 
maintaining pluripotency and regulating the differentiation of stem cells, but the role of DNA methylation 
in pancreatic CSC is obscure. In this study, we investigated the genome-wide DNA methylation profile of 
PDAC CSC and we determined the importance of DNMT methyltransferases for CSC maintenance and 
tumorigenicity. Using high-throughput methylation analysis, we discovered that sorted CSC have a higher 
level of DNA methylation, regardless of the heterogeneity or polyclonality of the CSC populations 
present in the tumors analyzed. Mechanistically, CSC expressed higher DNMT1 levels than non-CSC. 
Pharmacological or genetic targeting of DNMT1 in CSC reduced their self-renewal and in vivo 
tumorigenic potential, defining DNMT1 as a candidate CSC therapeutic target. The inhibitory effect we 
observed was mediated in part through epigenetic reactivation of previously silenced microRNAs, in 
particular the miR-17-92 cluster. Together our findings indicate that DNA methylation plays an important 
role in CSC biology, and also provide a rationale to develop epigenetic modulators to target CSC 
plasticity and improve the poor outcome of PDAC patients. 
 
Zagorac et al. – DNMT inhibition reprograms pancreatic cancer stem cells 
 
 
 
 
 
 
3
INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) represents the 4th most frequent cause of cancer-
related death due to its extreme lethality and current lack of effective treatments (1). As incidence and 
death rates continue to increase, pancreatic cancer is predicted to become the 2nd most frequent cause of 
cancer-related death by 2030 (2), making this disease a major unmet priority in public healthcare. While 
multiple subclonal populations of cancer cells coexist within each tumor and are assumed to drive tumor 
adaptation and therapeutic failure through Darwinian selection (3), convincing evidence now 
demonstrates that cancer heterogeneity is also driven by phenotypic and functional heterogeneity within 
each of these subclones, resulting in a hierarchical tumor organization (4). At the apex of this hierarchy 
are populations of cancer stem cells (CSCs) capable of self-renewal and long-term in vivo tumorigenicity. 
CSCs give rise to more differentiated progenies (non-CSCs), which, although sharing common mutation 
profiles, bear distinct and thus most likely epigenetically defined gene expression patterns (5,6). 
Identifying the epigenetic mechanisms that are responsible for the acquisition and preservation of 
these distinct CSC features could open up possibilities for the development of new and more effective 
therapeutic strategies for PDAC. Unlike genetic mutations, epigenetic changes are transient and 
reversible, and as such, therapies that convert the epigenetic balance of CSCs towards that of non-CSCs 
could provide the basis for developing more effective treatment strategies for cancer patients (7). Among 
the first epigenetic drugs proposed were inhibitors of DNA methylation, e.g. 5-azacytidine (5-aza-CR, 
azacitidine) and 5-aza-2′-deoxycytidine (5-aza-CdR, Decitabine), followed later by Zebularine, which all 
incorporate into DNA and form covalent irreversible complexes with DNA methyltransferases (DNMTs) 
(8). These inhibitors have been shown to induce differentiation of cultured cancer cells (9), but our 
knowledge about their effects on CSCs is still sparse. Moreover, to date only few studies have utilized the 
new DNA methylation inhibitor Zebularine, which can be administered orally and is less toxic (10). Thus, 
we aimed to characterize the supposedly distinct methylation profile of primary pancreatic CSCs and 
subsequently studied the effects of genetic or pharmacological targeting of DNMT1 on CSC phenotypes.  
Zagorac et al. – DNMT inhibition reprograms pancreatic cancer stem cells 
 
 
 
 
 
 
4
MATERIAL & METHODS 
Primary human cancer cells. PDAC tumors were obtained with written consent from all 
pancreatic cancer patients, expanded in immunocompromised mice as patient-derived xenografts (PDX), 
and subsequently digested to establish low-passage primary cell cultures (11).    
 In vivo tumorigenicity. Serial dilutions of primary pancreatic cancer cells were resuspended in 
MatrigelTM (BD, Heidelberg, Germany), subcutaneously injected into the right and left flank of female 
NU-Foxn1nu nude mice (Harlan Laboratories, UK), and tracked for up to 3 months. Experiments were 
approved by the Animal Experimental Ethics Committee of the Instituto de Salud Carlos III (Madrid, 
Spain; CBA 68_2013 & CBA 25_2009) and performed in accordance with the guidelines for Ethical 
Conduct in the Care and Use of Animals. CSC frequency was calculated using the extreme limiting 
dilution analysis (LDA) algorithm (http://bioinfo.wehi.edu.au/software/elda/index.html).   
 Sphere formation assay. Spheres were generated by culturing 2x103 PDAC cells per ml in ultra-
low attachment plates (Corning, NY, NY) using serum-free DMEM/F12 supplemented with B27 (1:50, 
Invitrogen, Waltham, MA), 20ng/ml bFGF, and 50units/ml penicillin/streptomycin for 7 days. For serial 
passaging, sphere cultures were first depleted for single cells and “spheres” measuring <40µm using a 
40µm cell strainer. Retained spheres were dissociated into single cells, re-cultured for another 7 days. 
Spheres >40μm were quantified with a CASY Cell Counter (Roche, Mannheim, Germany) (11). Primary 
sphere-derived human PDAC cells were treated with Zebularine (75µM) or Decitabine (50µM) for 7days. 
The drugs were re-administered every other day to the cell suspension. 
Flow cytometry analysis and FACS sorting. Primary pancreatic cells, dissociated spheres or cells 
from tumor digestions were stained with anti-hCD133/1-APC or PE (Miltenyi Biotec, Bergisch Gladbach, 
Germany), hEPCAM-APC (Miltenyi), hCD324-APC (Biolegend, London, UK), hPan-Cytokeratin-FITC 
(Miltenyi) or appropriate control antibodies (all from BD), counter-stained with DAPI (2μg/ml) for 
exclusion of dead cells and analyzed using a FACS CANTO II instrument (BD). Data were analyzed with 
FlowJo 9.2 software (Tree Star, Ashland, OR). For FACS sorting, cells were adjusted to a concentration 
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of 106 cells/ml in sorting buffer (1X PBS; 3% FBS (v/v); 3mM EDTA). DAPI was added to exclude dead 
cells, and cells were sorted using a FACS Influx instrument (BD).  
DNA methylation analysis. Genomic DNA (1µg) was treated by bisulfite conversion with the EZ 
DNA Methylation Kit (D5004, Zymo Research, Orange, CA) according to the manufacturer’s 
recommendations. The HumanMethylation450K BeadChip (Illumina, Inc, San Diego, CA) was used for 
analysis of genome-wide DNA methylation according to the manufacturer’s instructions. To identify 
differently methylated probes in paired autofluorescent-positive and -negative cells from all tumors, we used 
limma package (12). Probes were considered to be differentially methylated if the resulting adjusted P-value 
was <0.05. The Benjamini–Hochberg method was used to adjust the P-values and ensure that the false 
discovery rate was <0.05. The genomic region of the probes from the array were assigned according to their 
position relative to the transcript information obtained from the R/Bioconductor package 
FDb.InfiniumMethylation.hg19 (R package version 2.9.2). The CGI locations used in the analyses were 
obtained from the R/Bioconductor package FDb.InfiniumMethylation.hg19 (R package version 1.0.1). The 
definition of CGI was done as described previously (13). 
Statistical analysis. Results for continuous variables are presented as means ± SEM unless stated 
otherwise and significance was determined using the Mann-Whitney U test. All analyses were performed 
using SPSS 22.0 (SPSS, Chicago, IL). Significance was considered at p<0.05. 
 Additional experimental details can be found in the Supplementary Materials and Methods. 
 
RESULTS 
Pancreatic CSCs bear higher DNA methylation levels. We first performed genome-wide 
comprehensive methylation profiling using the 450K Illumina bead array (14) in order to gain insight into 
putative DNA methylation differences between CSCs and non-CSCs. CSCs can be separated from the 
tumor bulk population by several methods (11); however, we recently showed that PDAC CSCs can also 
be efficiently isolated using autofluorescence (an accumulation of riboflavin in ATP-dependent 
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transporter ABCG2-coated vesicles exclusively found in CSCs) (15). Using this CSC inherent marker, we 
separated CSCs from non-CSCs by FACSorting (Figure 1A) (15), and the efficient enrichment for CSCs 
was validated by increased expression of pluripotency-associated genes in autofluorescent-positive 
(Fluo+) CSCs versus Fluo– cells (Figure S1A/B).  
As the vast intratumoral heterogeneity in PDAC might obscure distinct methylation profiles 
between CSCs and non-CSCs within each contained subclone we did not only use cells derived from a 
heterogeneous primary pancreatic tumor (PDAC-185), but also analyzed a liver metastasis (PDAC-A6L), 
and a single cell-derived (SCD) tumor that was generated using a single CSC isolated from the primary 
tumor (PDAC-185 SCD) (Figure S1C/D). We reasoned that the CSC heterogeneity should be highest in 
the primary tumor, less in the metastatic tumor and homogenous in the CSCs isolated from the SCD 
tumor. DNA methylation levels were compared between CSCs and non-CSCs for each individual tumor, 
which revealed a slight, but significant increase in DNA methylation in the Fluo+ CSC compartment, 
regardless of the heterogeneity or polyclonality of the CSC populations present (Figure 1B). These data 
suggest consistent differences in the methylation profile despite considerable intratumoral heterogeneity. 
Furthermore, we looked at differentially methylated probes (hyper- or hypomethylation) in CSCs 
and found that their distribution was not universal. Hypermethylation was mostly located in non-CGI 
(Odds ratio[OD]=1.43) and intergenic regions (OR=1.17) and hypomethylation was mostly found in CGI 
(OR=1.80) and promoter regions (OR=1.43) (Figure 1C), indicating that the hypermethylation phenotype 
observed in the pancreatic CSC population is largely a result of methylation of regions that are outside of 
traditional CGI. To further confirm this observation, we measured the levels of the DNA methylation 
mark 5-methylcytosine (5mC) using the MethylFlash Methylated DNA Kit or by manual dotblot analysis 
and show that regardless of the method used to isolate CSCs (sphere vs adherent, Fluo+ vs Fluo–, or 
CD133+ vs CD133–), the CSC population exhibited consistently higher levels of 5mC, indicating that 
cytosine was methylated to 5-methylcytosine by DNMTs, which is in line with our Illumina Array data 
(Figures 1D & S2A).  
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Pancreatic cancer stem cells overexpress DNMT1. We next asked if hypermethylation could be 
explained by differential expression of DNMTs. Most strikingly, we found higher mRNA expression 
levels of DNMT1 in the CSC population, regardless of the isolation method used (Figures 2A, 2C & 
S2B). Western blot analysis confirmed higher DNMT1 protein expression in CSCs vs non-CSCs (Figure 
2B-D). Based on the above data, we reasoned that DNMT1 overexpression plays a decisive role in 
preserving the stemness state of CSCs via maintaining their distinct methylation state (16). 
DNMT1 inhibition decreases PDAC CSCs phenotypes. Based on the aforementioned results, we 
aimed to pharmacologically target DNMT1 using Zebularine (Zeb) in order to reverse the distinct 
methylome signature of CSCs and assess whether DNMT1 inhibition could ablate PDAC CSC 
tumorigenicity. Three primary PDAC cell cultures were treated with Zebularine over the course of 7 days 
in conditions that enrich for CSCs (Figure S3A/B). A concentration of 75µM was used in all of our 
subsequent experiments as cytotoxicity studies revealed that concentrations ≥100µM were potentially 
toxic (Figure S3C).  
While Zebularine expectedly showed minor or no effect on DNMT1 mRNA levels (Figure S3D), 
we observed a consistent inhibition of DNMT1 at the protein level (Figure 3A) and a marked reduction in 
CD133 mRNA and surface protein levels (Figure 3B), suggesting preferential targeting of CSCs. A 
similar reduction was observed when we sorted cells for autofluorescence to identify CSCs (Figure S3E). 
At the functional level Zebularine reduced both CSC self-renewal in vitro (Figure 3C) and the expression 
of pluripotency-associated genes (Figure 3D). To further corroborate that pharmacological inhibition of 
DNMT1 is suitable for targeting pancreatic CSCs, we used another DNMT inhibitor, Decitabine (DAC). 
Indeed, non-toxic levels of DAC (Figure S4A) decreased DNMT1 protein levels (Figure S4B) and 
subsequently reduced the self-renewal capacity of CSCs in three different PDAC cultures (Figure S4C). 
Moreover, DAC treatment significantly decreased the expression of the pluripotency-associated gene 
OCT3/4 (Figure S4D). The differential effects on the expression of pluripotency-associated genes 
between Zebularine and DAC may, at least in part, be related to differences in DNA-hypomethylating 
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properties of the drugs as previously suggested (17). Nonetheless, at the functional level, both DNMT1 
inhibitors significantly inhibited the CSC population. Since the most defining feature of CSCs is their 
ability to form tumors in vivo, we also performed limiting dilution in vivo tumorigenicity assays with 
control or Zebularine-treated cells to assess their tumorigenic potential. Zebularine-treated cells produced 
significantly fewer (and smaller) tumors resulting in a 5-6-fold lower calculated CSC frequency (Figure 
3E, left panel). Moreover, in tumors that did form, the percentage of CD133+ cells was markedly 
reduced (Figure 3E, right panel), already suggesting enhanced epithelial differentiation as a possible 
mechanism of action.  
Knockout of DNMT1 decreases CSCs phenotypes. DNMT1 inhibitors, including Zebularine and 
DAC, have a similar mode of action (incorporation into DNA as cytosine analogues). The formation of 
covalent adducts between DNA and trapped DNA methyltransferase protein can induce toxic effects, 
making it difficult to separate demethylating activity from cytotoxicity (18). Therefore, to genetically 
verify our hypothesis that DNMT1 is indeed crucial for maintaining the CSC status, we generated PDAC 
cells lacking DNMT1 via CRISPR/Cas9 editing. After two weeks under selection the 185 DNMT1-KO 
cells showed complete loss of DNMT1 expression at the protein level (Figure 4A). The subsequent loss 
of DNMT1 i) decreased the percentage of CD133+ CSCs (Figure 4B), ii) significantly abrogated the in 
vitro self-renewal capacity of CSCs as measured by multiple generation sphere-formation potential 
(Figure 4C), and iii) decreased the expression of pluripotency-associated genes (Figure 4D).  
The DNMT1 inhibition promotes CSC proliferation and differentiation. The effects of DNMT1 
inhibition on CSCs may be related to i) apoptosis induction, ii) cell cycle arrest, or iii) promotion of 
differentiation. Zebularine treatment during sphere formation did not significantly alter the percentage of 
early or late apoptotic cells in the entire tumor cell population (Figure 5A, left panel) nor was there any 
evidence of apoptosis induction specifically in the CD133+ CSC population (Figure 5A, right panel). 
Cell cycle analysis, however, revealed reduced numbers of Zebularine-treated cells residing in G0 and an 
increased number of actively cycling cells (Figure 5B). Moreover, not only did we observe a decrease in 
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the percentage of CD133+ CSCs upon treatment (Figure 3B), but by comparing ratios between the 
CD133– and the CD133+ cell populations, we found that the decrease in CD133+ CSCs was followed by 
an increase in their CD133-negative non-CSC counterparts, suggesting that Zebularine treatment 
potentially induced the “differentiation” of CSCs to non-CSC (Figure 5C). This result was confirmed by 
assessing the cell surface levels of pan-Cytokeratin and E-cadherin (Figures 5D-E and S5A-B) as 
markers of more differentiated PDAC cells (6). Higher expression of Pan-Cytokeratin and E-Cadherin 
could also be observed following DAC treatment (Figure S4E) and DNMT1 knockout (Figure S5C). 
Together, our data suggest a quiescence inhibiting and differentiation promoting effect of DNMT1 
inhibition on pancreatic CSCs.  
DNMT1 inhibition affects CSCs via hypomethylation of the miR-17-92 cluster. To determine 
the molecular mechanism(s) responsible for the effect of Zebularine on CSCs, we analyzed putative 
changes in DNA methylation using the Illumina Infinium HumanMethylation450 Bead Chip. As 
expected, Zebularine treatment decreased DNA methylation in PDAC CSCs (Figure 6A). Interestingly, 
while methylation of many genes was changed upon treatment, others even gained methylation. Using a 
stringent analysis approach (fold change in β-methylation values less than 0.5 and fold change higher than 
2) we found 97 and 548 genes demethylated and methylated, respectively (Tables S1 & S2). While these 
genes are currently under investigation, previous work by our group indicated that miRNAs (miR) have 
an important role in PDAC CSCs, and thus we initially focused our analysis on modulated miR. Indeed, 
as shown in Table 1, we identified several miR more methylated in CSC-enriched spheres versus non-
CSC adherent cultures, and using a less stringent analysis (fold change in β-methylation values 0.8) many 
were subsequently hypomethylated following Zebularine treatment (Table S3).  
Among these, we identified miR-203 and -205, which have previously been implicated in 
promoting cellular differentiation (19). While the expression of these miR could not be confirmed to be 
significantly altered by Zebularine (Figure S6A), we did see a strong and significant increase in the 
expression of these two miR in DNMT1-KO cells (Figure S6B). Next, we focused our attention on the 
Zagorac et al. – DNMT inhibition reprograms pancreatic cancer stem cells 
 
 
 
 
 
 
10
miR-17HG (miR-17-92 cluster host gene) as a potentially methylation-regulated miR as Zebularine 
treatment phenocopied previous data from our laboratory related to the miR-17-92 cluster in CSCs (20). 
We previously showed that suppression of this cluster was necessary for the maintenance of CSC 
phenotypes and artificial overexpression of miR17-92 members forces quiescent CSCs into an active cell 
cycle state (20). Likewise, previous reports have observed a CpG island in close proximity of the miR-17-
92 promoter (21). Encouraged by these findings, we further investigate whether hypermethylation of this 
CpG island could be responsible for the apparent suppression of this important miR cluster in CSC-
enriched spheres (20). Indeed, analysis of our methylation array data showed that CpG sites in close 
proximity of the miR-17-92 cluster were hypomethylated upon Zebularine treatment (Table S3). Using 
an independent set of CSC-enriched samples from various PDAC tumors, we observed a consistent and 
notable increase in the expression of several miR-17-92 members following Zebularine treatment (Figure 
6B), with a particular increase in miR-19a and miR-19b. Consistently, the increased expression of miR-
17-92 members, in particular miR-19b, was mimicked in cells lacking DNMT1 (Figure S6C). Of note, 
miR-92a, bearing a unique seed sequence distinguishing it from the other miR-17-92 family members, 
was not modulated by Zebularine treatment (Ctrl vs Zeb: 1.13±0.02-fold change, n.s.). Known targets of 
the miR-17-92 cluster, such as P21 (CDKN1A), TGFBR2, ACVR1B (ALK4), SMAD2, and SMAD4, have 
also been implicated in pancreatic CSC phenotypes including self-renewal and chemoresistance (11,20). 
We found that many of these genes were suppressed upon Zebularine treatment at both the mRNA and 
(Figure 6C) and protein levels (e.g. P21) (Figure 6D), recapitulating our previous findings (20), and 
suggesting that DNMT1 inhibition is capable of unlocking the epigenetic repression of this cluster in 
CSCs to reactivate repressed ‘anti-CSC’ miR.  
It has been shown that the MYC proto-oncogene family is also involved in the transcriptional 
regulation of miR-17-92 (22). MYC is generally overexpressed in PDAC, but we recently showed that 
MYC is actually suppressed in pancreatic CSCs (23), which may contribute to the specific reduced 
expression of the miR-17-92 cluster in these cells. Indeed, our methylation array data indicated that CpG 
Zagorac et al. – DNMT inhibition reprograms pancreatic cancer stem cells 
 
 
 
 
 
 
11
sites annotated to MYC were more methylated in CSCs (fold change Adh vs Sph: 1.57±0.18), which 
could be reversed by Zebularine treatment (fold change Ctrl vs Zeb: 0.80±0.02). We consistently found a 
significant increase in c-MYC mRNA levels in CSC-enriched spheres upon treatment with Zebularine 
(Figure 6E).  
Finally, in order to provide more conclusive evidence that the effects of DNMT1 inhibition were 
primarily mediated via reactivation of the miR-17-92 cluster, we performed loss-of-function experiments 
in the presence or absence of Zebularine. For this purpose, we plated primary PDAC cells in adherent 
conditions to obtain a predominantly differentiated PDAC culture and treated these cells for 24h with 
antagomiR targeting the various members of the miR-17-92 cluster to promote “stemness”, as previously 
described (20). Following antagomiR treatment we next plated the cells in ultra-low adhesion conditions 
(sphere culture) to foster the expansion of CSCs and then treated cultures with Zebularine to 
competitively reverse the effects on CSC phenotypes mediated via miR downregulation. Zebularine 
reversed the antagomiR-mediated enhancement of sphere formation (Figure 6F), supporting the 
conclusion that Zebularine mediates its inhibitory effects on CSCs, at least in part, by inducing the 
expression of the members of the miR-17-92 cluster, which functions to repress the expression of CSC-
promoting genes. 
DISCUSSION 
 
Recent advances in our understanding of CSC epigenetics provide important insights into how 
these cells acquire their specific stem-like characteristics, and at the same time sheds light on how CSCs 
can be successfully targeted using epigenetic-modifying agents (24). Our data demonstrate that pancreatic 
CSCs i) bear higher DNA methylation levels, ii) express high levels of the DNMT methyltransferase 
protein DNMT1 and iii) loose stemness upon pharmacological or genetic inhibition of DNMT1. While 
previous studies have already shown that DNMTs are overexpressed in other cancer tissues compared to 
normal tissue (25,26), herein we report specific up-regulation of DNMT1 in PDAC and provide data to 
support its role as an important epigenetic modifier in pancreatic CSCs. Intriguingly, demethylation of 
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pancreatic CSCs using the DNMT1 inhibitors Zebularine and Decitabine markedly reduced their CSC 
functions and properties, an effect that was regulated via DNMT1-mediated demethylation of the miR-17-
92 cluster promoter. These data are in line with reports for other cancers where DNMT1 was also found 
to be essential for the maintenance of stem cells (27,28), but we now also provide a mechanistic link in 
the context of PDAC by demonstrating the modulation of a crucial miR cluster. 
Epigenetic modifications are able to alter gene expression and have been shown to play a crucial 
role in stem cell function and maintenance (27,29). As CSCs and their more differentiated progenies share 
the same genetic background, epigenetic changes should account for the striking functional differences 
between CSCs and their non-tumorigenic progenies. Specifically, we recently demonstrated that even a 
single CSC could give rise to a tumor that recapitulated the functional heterogeneity of the original 
parental tumor at the pathological, biological and genetic levels (15). Thus, epigenetics and not genetics 
must be the underlying drivers of this intraclonal heterogeneity, which is indeed supported by our present 
finding that the genome of CSCs is hypermethylated compared to non-CSCs. Strikingly, DNA 
hypermethylation could not only be found in single-CSC-derived tumors that lack intratumoral 
heterogeneity, but also in tumors derived from metastatic lesions and even highly heterogeneous primary 
tumors. This finding supports the notion that hypermethylation is a consistent and robust differential 
factor between pancreatic CSCs and non-CSCs. At the DNA level, this hypermethylation phenotype was 
restricted to regions outside traditional CpG islands, specifically non-CpG islands and intergenic regions. 
In general, it has been shown that cancer cells exhibit hypomethylation of intergenic regions (30), which 
consequently could contribute to activation of transposable elements and genome instability. On the other 
hand, promoter regions of many CpG islands of tumor suppressor genes become hypermethylated 
resulting in their loss-of-function (31). Fortunately, using genome-scale methylation-screening 
approaches we have learned that a fraction of normally methylated CpG islands become hypomethylated 
and transcriptionally active in cancer cells (32). Moreover, some CpG islands located within the 3′ ends of 
genes (33) and in intergenic regions (34) exhibit hypermethylation in cancer cells. It is still unclear to 
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what extent methylation of these non-promoter CpG islands might affect gene expression and more 
importantly what is the subsequent result/phenotype in different populations of cancer cells. While further 
studies are necessary to address these specific questions in the context of CSCs, our data allude to a 
possible mechanism by which PDAC CSCs may protect their genome from undesirable transcription or 
instability, achieving better fitness for survival and growth than their more differentiated non-CSC 
counterparts.   
DNA methylation is evolutionarily ancient and associated with gene silencing in eukaryotes. It 
represents a key regulatory mechanism for the self-renewal and differentiation programs of embryonic 
stem cells (ESC) and of adult stem cells (35). Maintenance of their “stemness” state is conferred to the set 
of developmental transcription factors (OCT4, NANOG, and SOX2), occupying promoters of genes 
associated with self-renewal. Expression of these transcriptional regulators is usually controlled by CpG 
promoter methylation, and differentiation is accomplished by partial or full methylation of pluripotency-
associated genes resulting in their downregulation (36). Thus, it is conceivable to predict that treatment of 
CSCs with de-methylating agents would further up-regulate pluripotency-associated gene expression; 
however, we observed a downregulation of pluripotency factors indicating that the epigenetic wiring of 
CSCs is not only different than stem cells but that other epigenetic regulators are likely shaping the 
epigenetic landscape of CSCs. 
Zebularine, a cytidine analog, acts primarily as a trap for DNMT proteins by forming tight 
covalent complexes between DNMT proteins and DNA after Zebularine incorporation (10). It is believed 
that the anti-tumor effects of DNMT inhibitors, such as Zebularine or Decitabine, are largely due to the 
re-expression of tumor suppressor genes (37), which are often silenced in cancer cells. Indeed, we 
observed that treatment with Zebularine was able to alter methylation patterns of a number of genes in 
PDAC CSCs including miR genes, which are regulated by methylation and are known to be involved in a 
wide range of biological processes, including stem cell differentiation (29). In addition, several miR have 
been shown to be involved in promoting/maintaining stemness in cancers. For example, miR-145 and 
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miR-9, both well-known tumor-suppressors, were found to be suppressed in several human cancers (38) 
due to aberrant DNA methylation of their promoters. Thus, we sought to focus our investigation on miR 
genes and to identify specific CpG sites located in the proximity of various miR promoter regions in 
which Zebularine-mediated hypomethylation re-activated genes that were originally silenced in CSCs. 
We observed that the miR-17-92 cluster (comprised of six members – miR17, 18a, 19a, 19b, 20a and 92a) 
was hypermethylated in CSCs vs non-CSCs (Table 1). This finding is in line with recent studies from our 
laboratory showing that the miR-17-92 cluster is consistently downregulated in pancreatic CSCs (20). In 
this study we showed that gain-of-function, using forced overexpression of miR-17-92, reduced CSC self-
renewal capacity, in vivo tumorigenicity and chemoresistance. On the other hand, downregulation of this 
cluster (i.e. inhibition of miR-17-92 using antagomiR) in more differentiated cells had the opposite effect, 
imparting non-CSCs with CSC-like phenotypes. This effect was mediated by suppressing multiple 
members of the NODAL/ACTIVIN/TGF-β1 signaling cascade as well as downstream targets, such as P21, 
P57, and TBX3, all of which have been shown to be crucial for maintaining the stem-like state of 
pancreatic CSCs (11,20,39). Our data now further validate and expand upon these previous findings and 
provide novel insights into the epigenetic mechanism(s) controlling the suppression of the miR-17-92 
cluster in CSCs. We show, using different approaches, that re-activation of the miR-17-92 cluster 
following DNMT1 pharmacological or genetic inhibition augments the phenotype of PDAC CSCs.   
Unlike other DNMT inhibitors, Zebularine is more stable in aqueous solution and is less toxic in 
vitro and in vivo (40). Continuous exposure of various cancer cell lines to Zebularine has already been 
shown to selectively slow tumor cell growth, highlighting its potential value as a chemotherapeutic agent. 
It has previously been shown that Zebularine has anti-cancer effects in established PDAC cell lines, 
supposedly via induction of apoptosis and subsequent suppression of tumor growth in vivo (41); however, 
using primary low-passage PDAC cultures derived from equally low-passage PDX tumors we found no 
evidence for a direct pro-apoptotic effect. Instead, we show that Zebularine treatment forces normally 
slow-cycling CSCs into a more proliferative fast-cycling state, which has been previously linked to 
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chemosensitization via enhanced expression of miR-17-92 (42). Moreover, we observed a marked 
promotion of CSC differentiation as determined by the loss of “stemness” markers (e.g. CD133) and a 
gain in the expression of differentiation markers including CYTOKERATIN and E-CADHERIN. More 
importantly, these phenotypes were recapitulated using not only a different DNMT inhibitor, Decitabine, 
but also in DNMT1-KO cells, indicating that regardless of the approach used, the loss of DNMT1 results 
in the same phenotypic changes: loss of “stemness” and promotion of differentiation. 
We would like to highlight that we cannot exclude the possibility that other CSC inhibitory miR 
could be reactivated by Zebularine treatment (or DNMT1 inhibition). Indeed Table S3 shows that upon 
treatment with Zebularine, β methylation values of various miR genes were decreased. Based on this list 
and after careful review of the literature, we opted to focus on the two miR, miR-203 and miR-205, as 
both miR were previously described to play a role in the biology of pancreatic cancer (43,44). miR-203 
acts as a known suppressor of stem cell pluripotent factors; therefore, reactivation of miR-203 by 
hypomethylation might contribute to the reduced levels of pluripotency-associated genes observed 
following Zebularine treatment in PDAC CSCs. Overexpression of miR-203 has also been demonstrated 
to induce expression of E-CADHERIN by inhibition of the E-CADHERIN repressors ZEB1/2, which 
correlates well with our E-CADHERIN immunofluorescence studies presented herein (45). Thus, the pro-
differentiation effect of Zebularine can also be potentially explained by Zebularine-induced 
hypomethylation of miR-203, which has previously been described as an epithelial differentiation factor 
(19). Likewise, miR-205 is a well-known anti-cancer miR and is consistently downregulated in clinical 
pancreatic cancer samples including CSCs (44,46). miR-205 replenishment reduces the expression of the 
pluripotency/stem cell marker OCT3/4, the CSC marker CD44, and resensitizes cells to chemotherapy. 
Based on these findings we checked the expression of miR-203 and miR-205 in PDAC cells treated with 
Zebularine and deficient in DNMT1 (i.e. DNMT1-KO cells). While expression of these miR was not 
significantly changed during short-term treatment with Zebularine (Figure S6A), we noticed a strong and 
significant increase in DNMT1-KO cells (Figure S6B), suggesting that more potent and/or long-term 
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inhibition of DNMT1 is necessary for miR-203 and miR-205 reactivation. Collectively, we cannot 
exclude the possibility that other anti-CSCs miR could be reactivated following DNMT1 inhibition; 
however, our data support the hypothesis that reactivation of the miR-17-92 cluster is a dominating 
driving factor responsible for the inhibitory effects observed in the PDAC CSC population. 
We are still far from thoroughly understanding the role of DNMT1 in the context of CSC biology. 
Increasing evidence already suggests that DNMT1 protein expression promotes the development of 
PDAC, from normal tissue to pre-cancerous lesions (PanINs) to PDAC (47). Moreover, DNMT1 has been 
demonstrated to be essential for the maintenance of hematopoietic stem cells (HSCs)/progenitor cells 
(48), epidermal progenitor cells and leukemia stem cells (49). More recently, DNMT1 was also shown to 
be indispensable for mammary stem/progenitor cells and CSC maintenance, and functional inactivation of 
this gene drastically reduces mammary tumor formation (50). The sum of prior evidence and new insights 
from our study certainly highlight the important role that DNMT1 plays in cancer biology and at the same 
time support the continued development of more effective methylation inhibitors as a means of improving 
the clinical outcome of PDAC patients.  
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Table 1 – Hypermethylated miRs in CSC-enriched spheres  
has-miRNA FC_sph vs. adh 
hsa-miR548N 1.45 
hsa-miR1281 1.42 
hsa-miR1259 1.41 
hsa-miR1225 1.40 
hsa-miR130B/hsa-miR301B 1.40 
hsa-miR17HG 1.34 
hsa-miR1224 1.31 
hsa-miR22 1.26 
hsa-miR1227 1.26 
hsa-miR1226 1.25 
hsa-miR330 1.24 
hsa-miR135B 1.24 
hsa-miR585 1.21 
hsa-miR600 1.21 
hsa-miR375 1.20 
 
Given is the Fold Change (FC) of β-methylation values for  
spheres (sph) vs adherent (adh). Only data for FC ≥ 1.20 are shown. 
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FIGURE LEGENDS 
Figure 1 – Pancreatic CSCs bear higher levels of DNA methylation. (A) Flow cytometry 
analysis of autofluorescence in sphere-derived cells from PDAC-185 SCD (PDAC tumor derived from a 
single PDAC 185 autofluorescent cell), PDAC-185 (primary tumor), and PDAC-A6L (PDAC liver 
metastasis). (B) Box plots representing DNA methylation levels in representative pairs of autofluorescent-
negative and -positive cells from the indicated primary PDAC sphere-derived cultures (* P<0.05).  
(C) Distribution of differently methylated (M) probes based on their genomic location relative to CpG 
islands (CGI; upper panel). CpG island shores represent regions 0-2 kb from CpG islands, shelves 
indicate regions 2-4 kb from CpG islands. Distribution relative to the promoter (upstream the 
transcription start site), and intragenic and intergenic non-promoter regions (lower panel).  
(D) Quantification of 5mC using The MethylFlash™ Quantification Kit in non-CSCs vs CSCs (adh vs 
sph, Fluo– vs Fluo+, and CD133– vs. CD133+). Data are shown as fold change compared to non-CSC 
(mean±SD; n=3). 
Figure 2 – Pancreatic CSCs overexpress DNMT1.  (A) qRT-PCR analysis of DNMT1 mRNA 
in PDAC adherent (adh) and sphere (sph) cultures. Data are normalized to β-actin levels and represent 
pooled values from different primary PDAC cultures (A6L, 185, 354, and 215; * P<0.05; n=5). (B) 
Representative Western blot images of DNMT1 protein expression in a panel of different primary 
adherent and sphere-derived cultures (A6L, 185 and 354) and densitometric quantification (Quant.) (left 
panel). Changes in protein levels are depicted as fold change in pooled adherent cultures vs pooled 
sphere-derived cultures (* P<0.05; n=3). (C) Relative mRNA level of DNMT1 in CSCs (Fluo+ and 
CD133+) vs non-CSCs (Fluo– and CD133–; * p<0.05, n=3) (right panel).  (D) Representative Western 
blot images of DNMT1 protein expression in CSCs (CD133 positive) vs non-CSCs (CD133 negative) and 
densitometric quantification. 
Figure 3 – The DNMT1 inhibitor Zebularine decreases CSC phenotypes. (A) Scheme 
showing treatment strategy for Control (Ctrl) vs Zebularine (Zeb) in spheres (PDAC-A6L, -185, and -
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354) (left) and Western blot analysis of DNMT1 protein levels following treatment (middle). 
Densitometric quantification analysis (right) (* P<0.05; n=3). (B) qRT-PCR analysis of CD133 mRNA in 
PDAC sphere-derived cultures treated with Zebularine for 7 days. Data are normalized to β-actin and 
represented as fold change compared to untreated cells (left) (* P<0.05; n=3). Representative flow 
cytometry showing the percentage of CD133-positive and -negative cells from PDAC spheres treated for 
7 days with Zebularine (right). (C) Number of spheres per ml in 1st and 2nd generation cultures from 
primary PDAC tumors (A6L, 185 and 354; * P<0.05; n=4). (D) qRT-PCR analysis of pluripotency-
associated genes in 1st generation spheres. Data are normalized to β-actin and presented as fold change in 
comparison to untreated cells (* P<0.05; n=4). (E) Summary of in vivo tumorigenicity of subcutaneously 
injected Control and Zebularine-treated sphere-derived cells 12 weeks post-injection (left). CSC 
frequencies were determined using the extreme LDA algorithm. Representative flow cytometry plots 
showing the percentage of CD133 expression in digested tumors derived from Control and Zebularine-
treated cells (right).  
 Figure 4 – Knockout of DNMT1 decreases CSC phenotypes. (A) Western blot analysis of 
DNMT1 protein levels in Control (Cas9) and DNMT1-KO cells and densitometric quantification. (B) 
Representative flow cytometry plots of CD133 cell surface expression in Control (Cas9) and DNMT1-KO 
cells. (C) Representative images of spheres (left) and sphere counts (right) in 1st and 2nd generation in 
Control (Cas9) and DNMT1-KO cells (* P<0.05; n=3). (D) qRT-PCR analysis of pluripotency-associated 
genes in DNMT1-KO cells. Data are normalized to β-actin and presented as fold change in comparison to 
Control (Cas9) cells (* P<0.05; n=4).  
Figure 5 – Zebularine promotes CSC proliferation and differentiation. (A) Scheme of the 
treatment time course (left), AnnexinV expression in Control (Ctrl) and Zebularine (Zeb)-treated PDAC-
185, PDAC-354, and PDAC-A6L (n=3) (middle). AnnexinV expression determined within the CD133+ 
and CD133– fractions, using CD133-PE, for Zeb- and Ctrl-treated PDAC-185, PDAC-354 and PDAC-
A6L cultures (right). (B) Representative flow cytometry plots for Ki-67 staining in Control vs 
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Zebularine-treated PDAC-354 cultures (left panel) and combined quantification (right panel) (* P<0.05; 
n=6). (C) Quantification of flow cytometry analysis of CD133 expression in Control vs Zebularine-
treated spheres from PDAC-185 and PDAC-A6L (* P<0.05; n=3). (D) Quantification of the mean 
fluorescence intensity (MFI) of pan-CYTOKERATIN (pan-CK) staining in Control vs Zebularine-treated 
primary PDAC cultures (left) (* P<0.05; n=8). Representative confocal images are shown (right).  
(E) Representative confocal images of E-CADHERIN staining for Control vs Zebularine-treated cultures. 
 Figure 6 – The effect of Zebularine is mediated via hypomethylation of the miR-17-92 
cluster. (A) Box plots representing the decrease in DNA methylation levels in pooled Control vs 
Zebularine-treated PDAC cultures. * P<0.05. (B) qRT-PCR analysis of members of the miR-17-92 cluster 
(miR17, 18a, 19a, 19b, 20a) in PDAC-A6L and PDAC-185 sphere-derived cultures (* p<0.05; n=4). (C) 
qRT-PCR analysis of miR-17-92 target genes in PDAC-A6L and PDAC-185 sphere-derived cultures. 
Data are normalized to β-actin levels and represented as fold change compared to untreated cells (* 
P<0.05; n=3). (D) Western blot analysis of P21 protein levels in Control vs Zebularine-treated cultures 
(upper panel) and subsequent densitometric quantification (lower panel). Changes in protein levels are 
represented as fold change compared to untreated cells. (E) qRT-PCR analysis for MYC expression in 
PDAC-185 cells. Data are normalized to β-actin and represented as fold change in comparison to 
untreated cells (* P<0.05; n=4). (F) PDAC adherent cells were treated with antagomiR for miR-17, 18a, 
19a/b, and 20a for 24h. Cells were plated for sphere formation assay, treated with Zebularine for 7 days, 
and number of spheres per ml were determined (* P<0.05; n=6). 
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Figure 3 – DNMT1 inhibitor Zebularine decreases CSCs phenotypes 
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Cas9 Cas9 
+sgDNMT1 
Quant. 
F
o
ld
 c
h
a
n
g
e
 i
n
 m
R
N
A
 e
x
p
re
s
s
io
n
 
0.0
0.5
1.0
1.5
G0 G1 S G2/M
Ctrl Zeb
0.0
0.5
1.0
1.5
cd133- cd133+ cd133- cd133+ cd133- cd133+
185 354 A6L
0.0
0.5
1.0
1.5
185 354 A6L
Ctrl Zeb
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Ctrl Zeb
Figure 5 – Zebularine promotes CSC proliferation and differentiation  
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Figure 6 – Effect of Zebularine is mediated via hypomethylation of the miR-17-92 cluster 
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Figure S1 – Autofluoresence as a biomarker for pancreatic cancer stem cells 
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 C sgDNMT1 trl Zeb 
Gene_Name FC_Zeb vs Ctrl 
PRR3/GNL1 0.09 
LIFR 0.23 
UBE2G1 0.27 
KIAA1432 0.30 
ITSN1/CRYZL1 0.30 
HIST1H4K 0.33 
PITX1 0.34 
HIST1H3I 0.34 
HES2 0.34 
GARNL3 0.35 
LOC389333 0.37 
UXS1 0.37 
LANCL1/CPS1 0.38 
PCBD2 0.38 
SSTR5/LOC146336 0.39 
PSTK 0.39 
NDUFS6 0.40 
ADC 0.40 
ZBTB7A 0.40 
HIST1H2AJ/HIST1H2BM 0.40 
FOXP1 0.40 
EEF1A1 0.40 
HDHD2 0.40 
USP1 0.41 
MAPKBP1 0.41 
ZFP36 0.42 
SGK3 0.42 
TUBB2B 0.42 
GCLC 0.43 
SOX2OT/SOX2 0.43 
SHOX2 0.43 
UBAC2 0.43 
ILF3/LOC147727 0.43 
STX5 0.44 
HLA-DRB1 0.44 
SPEN/FLJ37453 0.44 
SGEF 0.44 
ECHDC2 0.44 
HIST1H4J 0.45 
MAP6D1 0.45 
LOC100130987/RAD9A 0.45 
VPRBP 0.46 
TMEM179B/TAF6L 0.46 
DOCK1 0.46 
PTGER3 0.46 
EFHC1 0.46 
ANKRD57 0.46 
TMEM108 0.46 
HIST1H4J 0.47 
ERICH1 0.47 
PLEK2 0.47 
Table S1 – Decreased DNA methylation of genes upon Zebularine treatment 
Gene_Name FC_Zeb vs Ctrl 
BCAR1 0.48 
ICT1 0.48 
RAB6A 0.48 
TCTE1 0.48 
MYADM 0.48 
ELAC2 0.48 
EIF3I 0.48 
ZNF784 0.48 
DPP3 0.48 
TRIM24 0.48 
BCCIP 0.48 
PSTPIP2 0.48 
PRKAG2 0.48 
LYST 0.48 
DUSP1 0.48 
C1orf210 0.48 
CBR1 0.48 
SIN3A 0.48 
KIAA0802 0.49 
NDE1 0.49 
C21orf96 0.49 
ALKBH5 0.49 
FRAS1 0.49 
ANKH 0.49 
IFNGR1 0.49 
ATP1A1 0.49 
KCNT1 0.49 
CDC6 0.49 
LEPR/LEPROT 0.49 
SLC7A6 0.49 
EZH2 0.49 
DCP1A 0.49 
HNRNPD 0.49 
C2orf63/RPS27A 0.49 
PCDHGA1 0.49 
GPX5 0.49 
BAT2L2 0.50 
HIST2H2AA3 0.50 
FAM119A 0.50 
MTCH1 0.50 
FDX1L 0.50 
TNPO3 0.50 
C7orf55 0.50 
AS3MT 0.50 
UNC84A 0.50 
Gene_Name FC_Zeb vs Ctrl 
LRP11 9.51 
HOXA3 9.20 
CMTM3 7.71 
TRMT11 7.27 
SFRS2IP 5.99 
LYN 5.06 
EXOC4 3.72 
TESK2 3.65 
RNF168 3.59 
SIVA1 3.54 
FKBP2 3.42 
TMEM160 3.17 
LPHN2 2.85 
METT10D 2.85 
CHD9 2.84 
RAD51 2.84 
ESYT1 2.76 
NFYA/C6orf130 2.74 
H2AFY2 2.73 
NAV1 2.72 
BLZF1/NME7 2.71 
C6orf192 2.70 
KCTD6 2.70 
SYCP3 2.69 
UTRN 2.69 
NEDD9 2.68 
FTO/RPGRIP1L 2.68 
BAI2 2.68 
ZNF518A 2.67 
BRCA2 2.66 
MAPKAP1 2.65 
SNORD50A/SNHG5 2.64 
ATN1 2.63 
TPM3 2.63 
KCTD11/ACAP1 2.63 
MAP7 2.62 
SF3B1 2.62 
SLC35A1 2.61 
ANO4 2.61 
DAXX 2.61 
KIF11 2.60 
ZNF613 2.60 
NCOA6 2.58 
ABCF1 2.58 
MACC1 2.58 
SNHG3-RCC1 2.57 
ZDHHC20 2.56 
C18orf54 2.56 
WHSC1L1 2.55 
HIST2H2AA4/HIST2H2AA3 2.55 
RFC3 2.55 
DAPK3 2.55 
RB1CC1 2.53 
LARS2 2.52 
Table S2 – Increased DNA methylation of genes upon Zebularine treatment 
Gene_Name FC_Zeb vs Ctrl 
DCUN1D4 2.51 
PCDHB10 2.51 
APP 2.50 
ALDH1A3 2.50 
MIR548I4/CNTNAP2 2.49 
MEF2D 2.49 
TRIM25 2.48 
IFNAR2 2.47 
KLC4/MRPL2 2.47 
CLUL1 2.47 
DTL 2.46 
MAP3K5 2.46 
OXCT1 2.45 
HIST1H4E 2.45 
FDFT1 2.45 
TMED10 2.45 
UGDH 2.45 
PJA2 2.43 
EIF3H 2.43 
PSMC2 2.43 
SOCS4/WDHD1 2.43 
OR5I1 2.43 
ELL2 2.42 
GRB2 2.42 
FUK 2.42 
ATP5J/GABPA 2.41 
HIST1H2BM/HIST1H2AJ 2.41 
BAT4/CSNK2B 2.41 
SOX2OT/SOX2 2.40 
CTNND1 2.40 
SYDE2 2.40 
SFRS12IP1 2.40 
NMI 2.40 
NCRNA00120/AKIRIN2 2.39 
GRB2 2.39 
PROX1 2.39 
USP13 2.39 
BAI3 2.39 
RBM47 2.39 
GLI1 2.38 
RAP2A 2.38 
RPLP2 2.38 
NAA16 2.38 
CDC14B 2.37 
MYO16 2.37 
PTP4A2 2.37 
BET1 2.37 
C1orf25 2.37 
SYNE2 2.37 
FLJ45244/DICER1 2.36 
HOXC11 2.36 
HSPC072/LOC100270804 2.35 
PSMA1 2.35 
GTF3A 2.35 
Gene_Name FC_Zeb vs Ctrl 
RNASEK 2.35 
C10orf53 2.35 
CD2AP 2.35 
PSMG2/CEP76 2.34 
KIAA1244 2.34 
DCP2 2.34 
CNN3 2.34 
BZW2/ANKMY2 2.33 
DLAT 2.33 
SLC7A11 2.33 
BTN2A1 2.33 
RAD54B 2.33 
C6orf165 2.33 
CYBASC3/TMEM138 2.33 
GNAO1 2.32 
MRPS30 2.32 
SIN3A 2.32 
SLC2A1 2.32 
ZNF259 2.32 
HIST1H2AC/HIST1H2BC 2.31 
B3GALT1 2.31 
RPL14 2.31 
API5 2.31 
TMEM87A 2.30 
MCM4 2.30 
NDC80/METTL4 2.30 
ATF6B 2.30 
PTPRD 2.30 
MAP4K1/EIF3K 2.30 
BRE/RBKS/LOC100302650 2.30 
MTRF1L 2.29 
SC4MOL 2.29 
TOLLIP 2.29 
LAMB2 2.29 
NT5DC3 2.29 
CBR4 2.29 
PRLR 2.29 
ARL5A 2.29 
PLK1 2.28 
IWS1 2.28 
SLC12A9 2.28 
HNRNPC 2.28 
NRP1 2.28 
NMT1/DCAKD 2.28 
IL17RD 2.27 
DAB2 2.27 
LOC552889 2.27 
UFD1L/CDC45L 2.27 
CDK6 2.27 
TSNAX-DISC1 2.26 
SEPHS2 2.26 
TMED7-TICAM2 2.26 
KRT10/TMEM99 2.26 
RNF111 2.26 
Gene_Name FC_Zeb vs Ctrl 
RPL7/RDH10 2.26 
C5orf44/TRIM23 2.26 
IMPAD1 2.25 
HARS 2.25 
SLC25A13 2.25 
CARD6 2.25 
KIAA0146 2.25 
PES1 2.24 
ZMYND11 2.24 
GTPBP8 2.24 
HARBI1/KIAA0652 2.24 
C12orf11/FGFR1OP2 2.24 
UBR5 2.23 
S100A10 2.23 
TMEM49/PTRH2 2.23 
VWC2 2.23 
FSIP1 2.23 
MRPS28 2.22 
HAX1 2.22 
LRRK1 2.22 
CASC5 2.22 
BRIX1/RAD1 2.22 
C7orf36 2.22 
ALK 2.22 
ZDHHC5 2.21 
ADAR 2.21 
LENG9 2.21 
NR1H3/ACP2 2.21 
LARP7/C4orf21 2.21 
MAP4 2.21 
PHF12 2.21 
IPMK 2.21 
VPS25 2.21 
C2orf60 2.20 
NFIL3 2.20 
KIAA0319L 2.20 
TBC1D4 2.20 
CBARA1 2.20 
MAGI1 2.20 
TP53BP1 2.19 
MIPOL1 2.19 
SLC1A3 2.19 
C17orf80/FAM104A 2.19 
MADD 2.19 
HIST1H1E 2.18 
ALG14 2.18 
SACM1L 2.18 
MRFAP1L1 2.18 
ALCAM 2.18 
MED7 2.18 
DTWD2 2.18 
DLG2 2.18 
SLC25A36 2.18 
ZNF773 2.17 
Table S2 – Increased DNA methylation of genes upon Zebularine treatment 
Gene_Name FC_Zeb vs Ctrl 
RAI14 2.17 
BRD2 2.17 
C14orf106 2.17 
KLF9 2.17 
C11orf65 2.17 
NUP98 2.17 
MRPS12/SARS2 2.17 
NUF2 2.17 
CHD3 2.17 
RRM2B 2.17 
COX7A2 2.17 
SERPINI1/PDCD10 2.16 
MED27 2.16 
C16orf71/ANKS3 2.16 
UFD1L/CDC45L 2.16 
BTAF1 2.16 
LHFP 2.16 
ZRANB2 2.16 
TRIM26 2.16 
POLR1A 2.16 
AGPAT1/RNF5/RNF5P1 2.16 
CCDC94 2.16 
ZBTB9 2.16 
DERL2/MIS12 2.15 
MIR548G/C3orf26 2.15 
ERGIC2 2.15 
LOC100216545 2.15 
ATF4 2.15 
SKA3/MRP63 2.15 
ARID2 2.15 
ANKRD34A/POLR3GL 2.15 
DEFA5 2.15 
MAT2B 2.15 
ZNF687 2.15 
CWC22 2.14 
MALAT1 2.14 
C4orf33 2.14 
LOC100190939/TPT1 2.14 
LIPH 2.14 
EIF3B 2.14 
MLX 2.14 
TMCO6 2.14 
SPATA17/GPATCH2 2.14 
PNPLA3 2.14 
C12orf76 2.14 
BAT3 2.13 
RPS27 2.13 
KDM1A 2.13 
PLEKHM1 2.13 
FBXW8 2.13 
SDAD1 2.13 
PGAP2/NUP98 2.13 
PSMB8 2.13 
SRPK1 2.13 
Gene_Name FC_Zeb vs Ctrl 
C6orf52/PAK1IP1 2.13 
ETAA1 2.13 
HSD11B1L/C19orf70 2.13 
ATF2/MIR933 2.13 
DLGAP5 2.13 
HIVEP3 2.13 
ALG14 2.13 
HERC4 2.12 
MRPS33 2.12 
C21orf54 2.12 
TNFRSF11A 2.12 
C16orf46 2.12 
RPL22 2.12 
MRPS14 2.12 
C10orf131 2.12 
HFE 2.12 
ADPRHL2 2.12 
PSPC1 2.12 
ARGLU1 2.11 
RAB12 2.11 
CAPZA1 2.11 
MRPS33 2.11 
LRCH3 2.11 
TMTC2 2.11 
LOC285830 2.11 
THNSL1/ENKUR 2.11 
TMTC2 2.11 
HIST1H2AB 2.11 
VTI1A/ZDHHC6 2.11 
USP39 2.11 
FAM109A 2.11 
TLE4 2.11 
TSN 2.11 
ROBO3 2.11 
C10orf114 2.10 
SV2C 2.10 
NECAB1 2.10 
TFIP11 2.10 
DCBLD2 2.10 
IPO11 2.10 
ZNF219/C14orf176 2.10 
PRIM2 2.10 
HNF1A 2.10 
C13orf38 2.10 
C12orf72 2.10 
FLJ43663 2.10 
MLH1/EPM2AIP1 2.10 
MRPS36 2.10 
HSBP1L1 2.10 
ANKFY1 2.10 
NCEH1 2.10 
PAPOLG 2.09 
LMBR1 2.09 
ZNF423 2.09 
Table S2 – Increased DNA methylation of genes upon Zebularine treatment 
Gene_Name FC_Zeb vs Ctrl 
WDR89 2.09 
HIST1H1D 2.09 
RPS11 2.09 
SP2 2.09 
SNW1/C14orf178 2.09 
KIAA0319 2.09 
EHBP1 2.09 
ZBTB4/POLR2A 2.09 
TMEM68/TGS1 2.09 
IMMT 2.09 
HM13 2.09 
TMF1 2.09 
INSIG2 2.09 
OSTC 2.09 
LPHN1 2.09 
PPP2R3C/KIAA0391 2.09 
PODNL1/DCAF15 2.09 
C7orf64/PEX1 2.09 
LSR 2.09 
ZNF184 2.09 
VEZF1 2.09 
ZNF705A/FAM66C 2.09 
ACCN1 2.09 
DLX2 2.09 
CHD7 2.09 
ANO4 2.09 
ABCF1 2.09 
UNC45A 2.08 
ELP3 2.08 
ZNF440 2.08 
CEP164 2.08 
KAT2B 2.08 
CYB5A 2.08 
CDV3 2.08 
NME7/BLZF1 2.08 
FKBPL 2.08 
PRNP 2.08 
ZNF426 2.08 
SLK 2.08 
KCTD21/USP35 2.08 
EHMT2 2.08 
APOC1 2.08 
SAPS2 2.07 
TPI1 2.07 
ASNSD1 2.07 
TMEM143/SYNGR4 2.07 
KLF9 2.07 
C2orf60 2.07 
CASC2/RAB11FIP2 2.07 
AHCYL1 2.07 
C13orf23/NHLRC3 2.07 
ZNF192 2.07 
AGPAT1/RNF5/RNF5
P1 2.07 
CHURC1 2.07 
Gene_Name FC_Zeb vs Ctrl 
ATP13A3 2.07 
VPS45 2.07 
KIAA0907 2.07 
SETD2 2.07 
ORC1L/PRPF38A 2.07 
BNIP1 2.07 
SFRS13A 2.07 
OSBP 2.07 
MPZL2 2.07 
WDR46/PFDN6 2.07 
KIAA0427 2.07 
ZFYVE26 2.07 
HIST1H2AC 2.07 
OGG1 2.07 
HELQ/MRPS18C 2.07 
MXI1 2.07 
SYF2 2.07 
TOMM7 2.07 
PTEN/KILLIN 2.07 
RNGTT 2.07 
NPC2 2.07 
CENPO 2.07 
KRAS 2.06 
RPUSD2 2.06 
RGS2 2.06 
SORL1 2.06 
LOC388789 2.06 
C1orf204 2.06 
C4orf3 2.06 
RPL24 2.06 
UBXN2A 2.06 
PRKG1 2.06 
MRPS36 2.06 
SETD5 2.06 
MEPCE/ZCWPW1 2.06 
CA8 2.06 
RPL7 2.06 
ITGAV 2.06 
MET 2.06 
FCF1/KIAA0317 2.06 
DDX18 2.06 
DPYD 2.06 
VTI1B 2.06 
CD8A 2.06 
SLC39A7/RXRB 2.05 
RPS6KC1 2.05 
SMARCAD1 2.05 
HOXA3 2.05 
CTDSPL2 2.05 
KCTD18 2.05 
HIST1H2BN 2.05 
CCND3 2.05 
SCARNA16/C17orf86 2.05 
RSL1D1 2.05 
Table S2 – Increased DNA methylation of genes upon Zebularine treatment 
Gene_Name FC_Zeb vs Ctrl 
BCO2 2.05 
C1orf31 2.05 
RUNX1 2.05 
CD55 2.05 
KIAA1522 2.05 
TIMELESS 2.05 
CCDC18/TMED5 2.05 
ATOX1 2.04 
TACO1 2.04 
NAPB 2.04 
PEX7 2.04 
C4orf32 2.04 
NCRNA00081/SHOC2 2.04 
WBP4 2.04 
TUFM 2.04 
TRIM27 2.04 
IRF2BP2 2.04 
RTTN 2.04 
HNRNPA1/CBX5 2.04 
EIF3E 2.04 
MOBKL1A 2.04 
ERCC5 2.04 
CRAMP1L 2.04 
ATP5G1 2.04 
RBPJL/MATN4 2.04 
PFDN6/WDR46 2.04 
GLCCI1 2.04 
S100A11 2.03 
FAM102B 2.03 
SFPQ 2.03 
HIST1H2AB 2.03 
SNORA7A/RPL32 2.03 
HNRNPM 2.03 
SLC35E3 2.03 
ANKRD11 2.03 
BUB1 2.03 
OR1E2 2.03 
ASAH1 2.03 
DARS 2.03 
CTDSP2 2.03 
PTTG1IP 2.03 
TMX4 2.03 
ANAPC7 2.03 
YARS 2.03 
RND3 2.03 
GBX1 2.03 
OSGEPL1 2.02 
CACNA2D3 2.02 
BAD/GPR137 2.02 
NRD1 2.02 
TRIM2 2.02 
TRPM5 2.02 
MACF1 2.02 
NUAK2 2.02 
Gene_Name FC_Zeb vs Ctrl 
KBTBD5 2.02 
C10orf140 2.02 
BDP1 2.02 
LANCL1/CPS1 2.02 
DPYSL2 2.02 
HIP1 2.02 
ZADH2/TSHZ1 2.02 
ROBO1 2.02 
FBXW8 2.02 
UBR4 2.02 
IFI16 2.02 
BTBD9 2.02 
ACAD11 2.02 
DTNBP1 2.02 
PCDH7 2.02 
ZFP36L2/LOC100129726 2.02 
PEX13 2.02 
MAF 2.02 
HIST1H2AG/HIST1H2BJ 2.02 
RASL11B 2.02 
ORC6L/VPS35 2.02 
RAB13 2.01 
SLK 2.01 
SPRY1 2.01 
CCDC49 2.01 
CCDC21 2.01 
CCDC14 2.01 
FBXL3 2.01 
KLHDC4 2.01 
TRIM45 2.01 
TBP 2.01 
AICDA 2.01 
RFXANK 2.01 
NUP188/ 2.01 
FBXO16 2.01 
UBP1 2.01 
GNAI3 2.01 
A2BP1 2.01 
AASDH 2.01 
GPM6A 2.01 
UBN2 2.01 
PIK3R3 2.01 
TAF11/ANKS1A 2.01 
LSG1 2.01 
TMEM67 2.01 
MSH5 2.01 
NPM1 2.01 
C9orf130 2.00 
RPL32P3 2.00 
SCGB2A2 2.00 
YWHAG 2.00 
CDC42EP3 2.00 
C19orf35 2.00 
EXOSC9 2.00 
Gene_Name 
 
FC_Zeb vs 
Ctrl 
NQO1 2.00 
ALS2CR4 2.00 
ANKRD10 2.00 
MTFMT 2.00 
MED17 2.00 
ARMC8 2.00 
MTX2 2.00 
ANGEL2 2.00 
Table S2 – Increased DNA methylation of genes upon Zebularine treatment 
hsa-miRNA FC_Zeb vs. Ctrl 
hsa-miR1470 0.61 
hsa-miR548G 0.61 
hsa-miR548G 0.69 
hsa-miR205 0.71 
hsa-miR1470 0.73 
hsa-miR205 0.73 
hsa-miR1470 0.74 
hsa-miR548N 0.77 
hsa-miR548N 0.78 
hsa-miR205 0.78 
hsa-miR548N 0.78 
hsa-miR548G 0.80 
hsa-miR1236 0.58 
hsa-miR548H4 0.62 
hsa-miR636 0.62 
hsa-miR203 0.69 
hsa-miR26B 0.70 
hsa-miR1236 0.70 
hsa-miR636 0.72 
hsa-miR423 0.75 
hsa-miR219-1 0.76 
hsa-miR148A 0.77 
hsa-miR26B 0.78 
hsa-miR423 0.78 
hsa-miR148A 0.78 
hsa-miR219-1 0.79 
hsa-miR548H4 0.79 
hsa-miR203 0.80 
hsa-miR760 0.61 
hsa-miR1915 0.62 
hsa-miR1324 0.63 
hsa-miR2277 0.67 
hsa-miR15B/miR16-2 0.68 
hsa-miR548F1 0.69 
hsa-miR2110 0.70 
hsa-miR346 0.70 
hsa-miR92B 0.71 
hsa-miR654/miR376B/miR376A2/miR300/miR376A1 0.71 
hsa-miR1292 0.72 
hsa-miR1322 0.72 
hsa-miR1539 0.72 
hsa-miR611 0.72 
hsa-miR129-1 0.72 
hsa-miR564 0.73 
hsa-miR132/miR212 0.73 
hsa-miR1205 0.73 
hsa-miR301B/miR130B 0.74 
hsa-miR548H3 0.74 
hsa-miR600 0.74 
hsa-miR27A/miR24-2/miR23A 0.75 
Table S3 – Decreased DNA methylation for miRs following Zebularine treatment 
Table S3 – Decreased DNA methylation for miRs following Zebularine treatment 
hsa-miRNA FC_ Zeb vs. Ctrl 
hsa-miR202 0.75 
hsa-miR570 0.75 
hsa-miR567 0.75 
hsa-miR585 0.76 
hsa-miR592 0.76 
hsa-miR375 0.76 
hsa-miR339 0.77 
hsa-miR191/miR425 0.77 
hsa-miR150 0.77 
hsa-miR130A 0.77 
hsa-miR17HG 0.78 
hsa-miR658 0.78 
hsa-miR149 0.78 
hsa-miR661 0.78 
hsa-miR548K 0.78 
hsa-miR1304 0.78 
hsa-miR574 0.78 
hsa-miR320A 0.79 
hsa-miR16-2 0.79 
hsa-miR30D 0.79 
hsa-miR1977 0.79 
hsa-miR190B 0.79 
hsa-miR638 0.79 
hsa-miR425 0.79 
hsa-miR758/miR1197/miR329-1/miR323 0.79 
hsa-miR596 0.79 
hsa-miR451/miR144 0.79 
hsa-miR10A 0.80 
hsa-miR639 0.80 
hsa-miR1252 0.80 
hsa-miR10B 0.80 
hsa-miR762 0.80 
hsa-miR1287 0.80 
hsa-miR141/miR200C 0.80 
hsa-miR26A2 0.80 
Given is the Fold Change (FC)  of β-methylation values for Zebularine (Zeb) 
treatment vs control (ctrl). Only data for FC ≤ 0.80 are provided. 
Due to the presence of different probes targeting the same miRNAs, some are shown more than 
once.  
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 SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1 – Autofluoresence as a biomarker for pancreatic cells stem cells. 
(A) mRNA levels for pluripotency-associated genes in Fluo+ vs Fluo– sorted cells; PDAC-185 and -A6L, 
n=6, * p<0.05. (B) Nanog protein expression in Fluo+ and Fluo– cells. Representative Western blot using 
β-ACTIN as loading control. (C) H&E histology of the PDAC-185 parental tumor (upper left). 
Representative FACS plot for sorting of single Fluo+ cells (upper right). Arising tumors following 
injection of single cells into immunocompromised mice were digested and sorted for Fluo+ and Fluo– 
cells. Representative FACS plot is shown (lower right). (D) mRNA levels for pluripotency-associated 
genes for the parental 185 tumor, the single Fluo+ cell-derived tumor, and for A6L tumors are shown. * 
p<0.05, n=3 (lower left). 
Supplementary Figure 2 – PDAC CSCs over-express DNMT1 and bear higher 5mC levels. 
(A) Representative images of dot blots showing levels of 5mC in marker-positive (Fluo-positive and 
CD133-positive) versus marker-negative (Fluo-negative and CD133-negative) cells. Quantification of 
5mC levels was performed by densitometry. (B) qRT-PCR analysis of DNMT1 in sorted PDAC-185 
sphere-derived autofluorescent-positive (Fluo+) and -negative (Fluo–) cells (* P<0.05; n=4).  
Supplementary Figure 3 – DNMT1 inhibitor Zebularine decreases CSC phenotype. (A) 
Representative FACS plots for the CSC marker CD133 in spheres versus adherent primary PDAC cells. 
(B) mRNA levels for the pluripotency-associated gene NANOG in CD133+ vs CD133– sorted cells; n=4, 
* p<0.05. NANOG and DNMT1 protein expression in CD133+ and CD133– PDAC-354 sorted cells. 
Representative Western blot using β-ACTIN as loading control. (C) Graph illustrating cytotoxicity 
following 24h treatment with increasing concentrations of Zebularine; n=3, * p<0.05. (D) mRNA levels 
for DNMT1 gene in control (Ctrl) versus Zebularine (Zeb) treated cells  n=3, * p<0.05. (E) 
Representative flow cytometry plots showing the percentage of Fluo+ cells from Control and Zebularine-
treated cells (left), together with quantification (right). Data are represented as fold change compared to 
control cells; n=4, * p<0.05.  
 Supplementary Figure 4 – DNMT1 inhibitor Decitabine decreased CSC phenotype. (A) 
Graph illustrating cytotoxicity following 24h treatment with increasing concentrations of Decitabine 
Zagorac et al. – DNMT inhibition reprograms pancreatic cancer stem cells 
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(n=3, * p<0.05). (B) Representative Western blot showing DNMT1 protein level in control and 
Decitabine-treated spheres together with densitometric quantification. (C) Number of spheres per ml in 
1st and 2nd generation cultures from various primary PDAC tumors (A6L, 185, and 354; * P<0.05, n=3). 
(D) qRT-PCR analysis of pluripotency-associated genes (NANOG, OCT3/4, SOX2, and KLF4) in 1st 
generation spheres. Data are normalized to β-ACTIN and presented as fold change compared to untreated 
cells, (* P<0.05, n=3). (E) Representative flow cytometry plots for E-CADHERIN and Pan-
CYTOKERATIN (Pan-CK) in control and Decitabine-treated cells (upper panel) together with 
quantification (lower panel). Data are represented as fold change compared to control cells (n=4, * 
p<0.05).  
Figure 5 – DNMT1 inhibitor Zebularine promotes CSC differentiation. (A) Representative 
images of pan-CYTOKERATIN (Pan-CK) staining for Ctrl versus Zeb-treated cells. (B) Representative 
flow cytometry plots for E-CADHERIN and Pan-CK surface expression in control and Zebularine-treated 
cells (left) together with quantification (right). Data are represented as fold change compared to control 
cells; n=4, * p<0.05. (C) Representative flow cytometry plots for Pan-CK surface expression in Cas9 only 
(control) and Cas9+sgDNMT1(DNMT1-KO) cells.  
 Supplementary Figure 6 – DNMT1 inhibition modulates expression of miR-203, miR-205, 
and the miR-17-92 cluster. (A) qRT-PCR analysis of miR-203 and -205 expression in control and 
Zebularine (Zeb)-treated cells. Data are normalized to  Snord44 and presented as fold change compared to 
untreated cells. (B) qRT-PCR analysis of miR-203 and miR-205 in control (Cas9) and DNMT1-KO 
(Cas9+sgDNMT1) cells. Data are normalized to Snord44 and presented as fold change compared to 
control cells (n=4, * p<0.05). (C) qRT-PCR analysis of members of the miR-17-92 cluster (miR17, 18a, 
19a, 19b, and 20a) in control and DNMT1-KO sphere-derived cells (* p<0.05, n=3).   
 
 
 
 
 
 
 
SUPPLEMENTARY  
MATERIALS & METHODS 
 
 
            Primary human cancer cells.  The single cell-derived (SCD) tumor was generated by 
injecting a single autofluorescent positive CSC isolated from PDAC-185 (1). For in vitro studies, 
PDX tumors were minced, enzymatically digested with collagenase (Stem Cell Technologies, 
Vancouver, BC) for 60 min at 37°C and after centrifugation for 5 min at 1,200 rpm the pellets 
were resuspended and cultured in RPMI medium (Roswell Park Memorial Institute) 
supplemented with 10% fetal bovine serum (FBS) and 50units/mL penicillin/streptomycin. 
Illumina methylation array. Total DNA was isolated using standard phenol-chloroform 
extraction. Bisulfite converted DNA was isothermally amplified at 37°C (20-24h). The amplified 
DNA product was fragmented by an endpoint enzymatic process. Fragmented DNA was precipitated, 
resuspended, and applied to an Infinium Human Methylation450K BeadChip  (this array allows for 
the comparison of the DNA methylation status of 485,578 CpG loci across samples, covering all 
RefSeq genes at single-nucleotide resolution, microRNAs and differently methylated regions) and 
hybridized at 48°C (16-24h). During hybridization, the amplified and fragmented DNA samples 
anneal to specific oligomers covalently linked to the different bead types. The bead chips were then 
subjected to a single-base extension reaction. This reaction incorporates labeled nucleotides into the 
extended primers hybridized to DNA on the BeadChip. For methylation analysis, IDAT files were 
loaded into the R environment using the Bioconductor minfi package 3. The arrays were then 
background and control normalized using the minfi package. Technical differences between Infinium 
I and Infinium II probes were removed using Subset-quintile Within-Array Normalization, developed 
by Maksimovic et al. and available in the minfi package (2). The methylation status for each probe 
was recorded as a β-value.    
Genomic region analysis. A probe was marked to be in a ‘‘promoter’’ region if it was located 
in the first exon, the 5' UTR, or a region up to 2 kbp upstream of the transcription start site (TSS) of 
any given transcript. Similarly, an ‘‘intragenic’’ probe was labeled if it was inside any intron or any 
exon other than the first. Intergenic probes were determined as those not falling into either of the two 
previous categories. A contingency table was built for each subset of probes and genomic regions, 
with one variable indicating whether a given probe belonged or not to the subset, and the other 
indicating whether a given probe was labeled with the selected region. Significance of the association 
was determined by a Pearson’s Chi-squared test with Yates’ continuity correction. A significance 
level of 0.05 was used to determine whether a subset was dependent with respect to a given genomic 
region and an odds ratio was used as a measure of effect size. 
CGI status analysis. The CGI locations used in the analyses were obtained from the 
R/Bioconductor package FDb.InfiniumMethylation.hg19 (R package version 1.0.1). The definition of 
CGI was done as described previously (3). Specifically, ‘‘CpG shores’’ were defined as the 2-kbp 
regions flanking a CGI. ‘‘CpG shelves’’ were defined as the 2-kbp regions either upstream of or 
downstream from each CpG shore. Probes not belonging to any of the regions previously mentioned 
were assigned to the category ‘‘non-CGI.’’ Each probe was assigned to only one of the categories. In 
order to study the association between the given subset and the different CGI categories a 4-3-2 
contingency table was constructed for every subset of probes. Firstly, a Chi-squared test was used to 
determine if any of the categories had a significant association with the given subset. Additionally, a 
2-3-2 contingency table was defined and another Chi-squared test was used to independently evaluate 
the association of the given subset with each status level, a significance level of 0.05 being employed 
for all tests. Effect size was reported as the odds ratio for each of the individual tests. 
AntagomiRs. The miR-17-92 cluster was knocked down using a mix of hsa-miR-17, 18a, 
19a, 19b, and 20a antagomiRs (1.2μM each) or scrambled control. All antagomiRs were 
chemically synthesized as 2-O-methyl-oligoribonucleotide phosphorothioates containing 
cholesterol as modification of the 3’ end to facilitate cellular uptake  (BioSpring, Frankfurt, 
Germany).  
Cell viability assay. Cells were seeded in 96-well plates (Nalgen Nunc International, 
Penfield, NY) at a concentration of 104 cells per well in 100µL of complete medium, allowed to 
attach for 24h and then treated with Zebularine or Decitabine for an additional 24h. Cytotoxicity 
was assessed using a bioluminescence-based Toxilight BioAssay assay following the 
manufacturer’s recommendations (Lonza, Basel, Switzerland). All the experiments were done in 
triplicates. 
Apoptosis assay. Cancer cells and CSCs were plated at 3x105 cells/well in 6-well multi-well 
plates and cultured in the presence of Zebularine (75μM) for the indicated days. Attached and floating 
cells were collected, resuspended and stained for the CSC surface marker CD133 prior to staining 
with AnnexinV (550474) in AnnexinV binding buffer (556454; both from BD Pharmingen, San Jose, 
CA). Cells were then stained with DAPI and analyzed by flow cytometry.   
Cell cycle analysis.  Cells were trypsinized, washed in PBS, centrifuged, and pellets were 
fixed in 200µl of 70% ethanol and stored at -20°C until use. Cells were centrifuged and pellets 
resuspended in 200µl of PBS containing 10µg/mL of RNAse A and incubated for 1h at 37°C. Cells 
were then stained with DAPI and analyzed by flow cytometry. For the identification of G0 quiescent 
population, cells were fixed in 70% ethanol at -20°C overnight, washed with PBS twice and stained 
with Ki67 (BD) for 30min at room temperature, followed by an additional wash with PBS. Cells were 
stained with DAPI to perform cell cycle analyses using a FACS CANTO II (BD) instrument. 
Protein extraction and Western blotting. Cells were harvested in RIPA buffer (Sigma-
Aldrich, St. Louis, MI) supplemented with a protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN). The cell lysate was centrifuged at 14,000 rpm and the supernatant was 
collected. Protein lysates were quantified using a BCA Protein Assay Reagent kit (Pierce, 
Thermo Scientific, Waltham, MA). 50µg of protein was resolved by SDS-PAGE and transferred 
to nitrocellulose membranes (Amersham, Piscataway, NJ). Membranes were sequentially blocked 
with 1X TBS containing 5% BSA (w/v), or 5% (w/v) milk and 0.1% Tween20 (v/v), incubated 
with a 1:1,000 dilution of antibodies against NANOG (D73G4; Cell signaling); α-TUBULIN 
(#2144; Cell Signaling Tech, Danver, MA), β-ACTIN (Sigma-Aldrich), DNMT1 (D63A6; Cell 
signaling), and P21 (12D2; Cell Signaling) overnight at 4ºC, washed three times with 1X PBS 
containing 0.1% Tween20 (v/v), incubated with horseradish peroxidase-conjugated goat anti-
rabbit or goat anti-mouse antibody (Sigma-Aldrich), and washed again to remove unbound 
antibody. Bound antibody complexes were detected with SuperSignal chemiluminescent substrate 
(GE Healthcare, Little Chalfont, UK).   
RNA extraction and RT-qPCR. Total RNA was isolated by the guanidine thiocyanate 
method using standard protocols (4). One µg of purified RNA was used for cDNA synthesis 
using the QuantiTect Reverse Transcription Kit (Qiagen), followed by SYBR green RTqPCR 
using an Applied Biosystems 7500 real-time thermocycler (Applied Biosystems. Waltham, MA). 
Thermal cycling consisted of an initial 10min denaturation step at 95°C followed by 40 cycles of 
denaturation (15sec at 95°C) and annealing/extension (1min at 60°C). For miR analysis, 1µg of 
total RNA was reverse-transcribed using the NCode VILO miR cDNA synthesis kit according to the 
manufacturer's recommendations (Invitrogen, Waltham, MA). This step adds a polyadenylate tail to 
the miR population within the total RNA samples. The resulting cDNA was subjected to real-time 
PCR using SYBR Green ER qPCR Mix (Invitrogen). The Universal qPCR Primer was provided in the 
VILO kit and the forward primer for miR-17, 18a, 19a, 19b, 20a, 92a, 203, 205 Snord95 and Snord44 
were purchased from Qiagen or Exiqon (Vedaek, Denmark).  
 
List of primers used for RT-qPCR 
5mC quantification. Standard protocol was followed for the manual dot blot analysis. 
Briefly, DNA samples were diluted with TE buffer, denatured by heating to 99°C for 5min, 
chilled rapidly on ice and then loaded on a Hybond N+ nylon membrane (GE Health, Piscataway, 
NJ, USA). DNA was cross-linked using a Hoefer™ UVC 500 Ultraviolet Crosslinker (70,000 
micro-joules/cm2). After crosslinking, membranes were blocked with 5% fetal bovine serum 
(BSA) for 1 h at room temperature, and then incubated with a polyclonal anti-5mC antibody 
(Active Motif, Carlsbad, CA, USA; #39649, 1:250) at 4°C overnight. 5mC was visualized by 
chemiluminescence. For quantification of 5mC we used the MethylFlashTM Methylated DNA 
Quantification Kit (Epigenetek; P-1034-96). In brief, 200 ng of DNA was added to the wells and 
subsequent quantification of 5mC was performed following the manufacturer’s instructions.  
CRISPR/Cas9-mediated knockout of DNMT1. In order to disrupt DNMT1, two sgRNAs 
targeting the CDS were designed according to http://crispr.mit.edu. Specific guide RNAs were 
synthesized as complimentary oligos, phosphorylated with T4 polynucleotide kinase (New 
England Biolabs), annealed, and cloned into the BbsI (New England Biolabs) site of pKLV-
U6gRNA/BbsI-PKG-puro2A-BFP. The ligation mixture was transformed into OneShot 
chemically competent DH5alpha cells (Invitrogen). After plasmid DNA extraction (Qiagen), the 
sequence of the construct was verified by automated DNA sequence analysis. Replication-
incompetent lentiviral particles, contacting two different sgRNAs were produced in HEK293T 
following PEI-based transfection of cells with the packaging plasmids pCDNA3.1-VSV-G and 
pPAX2, as well as either one of the sgRNA plasmids. Forty-eight hours post transfection the medium 
was collected, cleared by low-speed centrifugation, filtered through 0.45µm pore-size PVDF filters, 
and stored in aliquots at -80ºC.  The viruses were subsequently titered by flow cytometry analysis of 
BFP expression in 293T cells infected with increasing dilutions of virus. 185 PDAC cells stably 
expressing Cas9 were infected with viruses containing both DNMT1 sgRNAs at MOI=5 and selected 
with puromycin (1.5µg/ml) for 2 weeks. Loss of DNMT1 expression was confirmed by western blot 
analysis.  
Sequences of CRISPR sgRNA used in this study: 
 
NAME sgRNA sequence (5′–3′) 
DNMT1 gRNA#1 (forward) CACCGCGCTGCCCGACGATGTCCGC 
DNMT1 gRNA#1 (reverse) TAAAACGCGGACATCGTCGGGCAGCGC 
DNMT1 gRNA#2 (forward) CACCGTGCCCGACGATGTCCGCAGG 
DNMT1 gRNA#2 (reverse) TAAAACCCTGCGGACATCGTCGGGCAC 
 
  Immunofluorescence.  Primary pancreatic cancer cells were seeded on cover slips in 6-well 
culture dishes (Corning, One Riverfront Plaza, NY) and treated with Zebularine. Following 7 days of 
treatment, cells were washed twice with 1X PBS, fixed with 4% formaldehyde for 10 min and 
blocked for 5 min with 10% heat inactivated normal donkey serum. After blocking, cells were 
permeabilized with 0.2% Triton X-100 for 10 min and incubated with the following antibodies: anti-
Cytokeratin (CK3-6H5)-FITC (1:10, # 130-080-101 Miltenyi Biotec) and anti-E-Cadherin (1:50;  
# 610182 BD Biosciences). For E-Cadherin staining, cells were washed two times with 1X PBS and 
stained with Alexa-Fluor555-conjugated secondary antibody (1:500; # 558617 BD Biosciences). The 
nuclei of cells were stained with DAPI (5μg/ml; Sigma, St. Louis, MO) and cover slips were analyzed 
using an LSM-710 confocal microscope (Leica, Heidelberg, Germany). 
Immunohistochemistry. For histopathological analysis, FFPE blocks were serially sectioned 
(3µm thick) and stained with hematoxylin and eosin (H&E).   
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